Skip To Main Content
Louis Cicchini on Muck Rack

Louis Cicchini

(He/Him)
Denver
As seen in: Pharmaceutical Executive, Drug Discovery & Development, Cell & Gene, Modern Retina
Covers:  Drug development Advanced therapies Cell and gene therapy FDA, CBER, OTP Regulatory compliance and affairs
Doesn't Cover: COVID, traditional pharmaceuticals, prophylactic vaccines

Get in touch with Louis

Contact Louis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Louis Cicchini’s Biography

Read Full Bio →

I am a scientific thought leader with 10+ years of experience spanning molecular biology, immunology, oncology, and cell & gene therapy. With a PhD in molecular biology, my research explored HPV persistence and immune evasion in cancer progression.

Transitioning into industry, I now focus on scientific affairs, commercial strategy, and partnerships to drive drug development and patient impact. I thrive at the intersection of science and business, ensuring innovative therapies reach the market e…

Louis Cicchini’s Journalist Portfolio

See all →
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships | PharmExec

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships | PharmExec

A successful transition from clinical development to commercial launch in cell and gene therapy requires earl…

View article →
Q&A for innovators: Navigating the complex regulatory world of ATMPs/CGTs | Cencora

Q&A for innovators: Navigating the complex regulatory world of ATMPs/CGTs | Cencora

Navigating the complex world of ATMPs and CGTs? Explore this Q&A to better understand the key regulatory diff…

View article →
Reducing the risk of CRLs for CGTs

Reducing the risk of CRLs for CGTs

How cell and gene therapy manufacturers can lessen the chances of receiving FDA complete response letters thr…

View article →
How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proact...

How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proact...

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters throug…

View article →
Strategies to drive accessibility and commercial success

Strategies to drive accessibility and commercial success

The cell and gene therapy (CGT) field is advancing rapidly. An ongoing parade of standout innovations is now…

View article →
The future promise of advanced therapies in ophthalmology

The future promise of advanced therapies in ophthalmology

Cell and gene therapies in development for unmet needs.

View article →

Interview

See all →

What was your first job as a journalist?

In grad school

Have you ever used a typewriter?

Yes

How is social media changing news?

Mostly polluting the space with noise and attention seekers